WilmerHale represented Thermo Fisher Scientific in a transaction with GE Healthcare announced today. Thermo Fisher has agreed to sell its cell culture (sera and media), gene modulation and magnetic beads businesses to GE Healthcare for approximately $1.06 billion. The businesses will become part of GE Healthcare’s Life Sciences division.
WilmerHale Partner Hal Leibowitz led the team advising Thermo Fisher. Other members on the WilmerHale team included partners from the corporate, tax, benefits, real estate and IP practices: Jeffrey Hermanson, Joseph Conahan, Rob Burke, Amy Null, Keith Barnett, Paul Jakubowski and Steve Barrett.
A press release discussing the transaction in greater detail is available on Thermo Fisher’s website.
